Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume 7, Issue 1, Pages 67-73Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17512433.2014.862496
Keywords
angiogenesis; drug development; renal cell cancer; targeted therapy
Categories
Funding
- GSK
Ask authors/readers for more resources
Although targeted therapy against VEGF and mTOR have revolutionized the treatment of advanced renal cell carcinoma (RCC), additional agents are required due to toxicity and resistance to currently available drugs. Some next-generation tyrosine kinase inhibitors have focused on VEGF, narrowing the spectrum of receptors which are inhibited and enhancing binding affinity. However, targeting novel receptors with tyrosine kinase inhibition of additional receptor targets has also emerged as an important future therapeutic strategy for RCC, both clear cell and variant histology. New pathways being targeted include FGF, angiopoietin and MET. In this review, we highlight five novel tyrosine kinase inhibitors in development for RCC: tivozanib; dovitinib; regorafenib; cabozantinib; and tivantinib.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available